Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE) (ROPE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04770064|
Recruitment Status : Withdrawn (Funding was not awarded)
First Posted : February 25, 2021
Last Update Posted : July 29, 2022
|Condition or disease||Intervention/treatment||Phase|
|Osteoarthritis, Knee||Drug: High-dose/short-duration Fisetin Drug: Low-dose/sustained-duration Fisetin Other: Oral placebo capsule||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)|
|Estimated Study Start Date :||June 2023|
|Estimated Primary Completion Date :||May 31, 2024|
|Estimated Study Completion Date :||May 31, 2024|
|Experimental: High-dose/short-duration Fisetin (FIS-hi)||
Drug: High-dose/short-duration Fisetin
Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
|Experimental: Low-dose/sustained duration Fisetin (FIS-lo)||
Drug: Low-dose/sustained-duration Fisetin
Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
|Placebo Comparator: Placebo||
Other: Oral placebo capsule
Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
- Change in markers of liver toxicity [ Time Frame: Change between baseline and 3-month follow-up ]The change in 2 markers of liver toxicity between baseline and 3-month follow-up will be assessed. Alanine amino transferase (ALT) and aspartate amino transferase (AST) are enzymes found mostly in the cells of the liver and kidney, and heart and liver, respectively. Both are useful tests for detecting liver damage.
- Change in markers of kidney toxicity [ Time Frame: Change between baseline and 3-month follow-up ]The change in 2 markers of kidney toxicity between baseline and 3-month follow-up will be assessed. Blood urea nitrogen (BUN) is a waste product filtered out of the blood by the kidneys. As kidney function decreases, the BUN level rises. Creatine kinase (CK) is also an enzyme that is used to assess kidney function. Higher CK values are associated with greater burden on the kidneys.
- Change in markers of tumor lysis syndrome [ Time Frame: Change between baseline and 3-month follow-up ]Tumor lysis syndrome is characterized by high blood potassium, low blood calcium, and high blood uric acid. The change in potassium, calcium and uric acid between baseline and 3-month follow-up will be assessed.
- Pain Visual Analogue Scale (VAS) [ Time Frame: Change between baseline and 3-month follow-up ]The Pain VAS is a 100 mm scale where participants will be asked to report their level of pain over the past 24 hours, with 0 being associated with no pain and 100 mm being associated with the worst pain imaginable.
- Western Ontario and MacMaster Universities Osteoarthritis Index (WOMAC) [ Time Frame: Change between baseline and 3-month follow-up ]The WOMAC is a 24-item instrument that has been found to be valid and responsive when quantifying changes in pain and function in individuals with knee osteoarthritis. Scores range from 0 to 96 with higher WOMAC scores being associated with worse pain, stiffness, and functional limitations.
- Five times sit-to-stand test [ Time Frame: Change between baseline and 3-month follow-up ]The five-repetition sit-to-stand is commonly used to measure mobility and function in older adults. Participants are positioned in a standard 16" office chair with their arms at their sides and back located against the back of the chair. Participants are instructed to "Please stand up straight as quickly as you can 5 times, without stopping in between. Keep your arms folded across your chest. I'll be timing you with a stopwatch. Ready, begin." The test is timed using a stopwatch and the timer is stopped when the individual achieves a standing position on the 5th trial. Faster times are associated with less functional impairment.
- Biomarker of cellular senescence (MMP-3) [ Time Frame: Change between baseline and 3-month follow-up ]Matrix metalloproteinase-3 (MMP-3) is commonly associated with senescence-associated secretory phenotype, and have been previously used to assess the mechanism of action of fisetin in human clinical trials. Greater serum concentrations of MMP-3 are associated with increased senescent cell activity.
- Biomarker of cartilage breakdown (CTXII) [ Time Frame: Change between baseline and 3-month follow-up ]C-terminal crosslinked telopeptide type II collagen (CTXII) has been identified as a biomarker for the diagnosis, staging, and evaluating the prognosis of hip and knee osteoarthritis, and has also been demonstrated to be responsive over short testing periods (3 months). Greater concentrations are associated with increased cartilage breakdown. CTXII will be measured in the urine and will be normalized to creatinine levels.
- Need for rescue treatment [ Time Frame: 3-month follow-up ]We will record the prevalence and time to rescue intra-articular injections such as a corticosteroid injection.
- Treatment Adherence [ Time Frame: 3-month follow-up ]Participants will be asked to complete an adherence questionnaire weekly throughout the study period. Participants will be contacted via their preferred method (phone, email, SMS text message). Previous literature has defined good medication compliance as taking at least 80% of the prescribed medication. We will calculate the proportion of patients who meet this criterion in the treatment group as well as the 95% confidence interval (CI) around this compliance rate. The treatments will be considered feasible and acceptable if over 70% of participants reach this threshold.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04770064
|United States, Kentucky|
|UK Healthcare at Turfland|
|Lexington, Kentucky, United States, 40504|
|UK HealthCare Joint Reconstruction and Replacement|
|Lexington, Kentucky, United States, 40508|
|Principal Investigator:||Austin Stone, MD, PhD||University of Kentucky|